First Therapy for Advanced Head & Neck Cancer in 10 Years: Johnson & Johnson Secures Accelerated FDA Nod

On Thursday, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Johnson & Johnson's (NYSE:JNJ)/a> Rybrevant Faspro as a single agent for adults battling recurrent or metastatic head and neck squamous cell carcinoma (HCSCC).

Eligible patients include those whose cancer progressed during or following platinum-based chemotherapy and an anti-PD-(L)1 antibody. The label excludes HPV-associated oropharyngeal squamous cell carcinoma.

This is the first approval in 10 years of a drug for patients with recurrent or metastatic HNSCC who had received prior platinum-based chemotherapy. /p> div class="bz-read-next-block" data-variant="card" data-news-mode="manual" >

strong> Read Also: a href="https://www.benzinga.com/news/health-care/26/09/61998704/johnson-johnson-clinical-trials-show-progress-across-key-therapies" target="_blank" rel="noopener"> Johnson & Johnson Clinical Trials Show Progress Across Key Therapies/a> /strong> /p>

Expanding Beyond Lung Cancer

The milestone represents the treatment's first approved indication outside non-small cell lung cancer.

The therapy targets both EGFR and MET pathways simultaneously while activating immune-cell directing activity, delivered via a five-minute subcutaneous injection.

Both receptors act as key drivers of tumor growth, overexpressed in 80% to 90% of recurrent and metastatic tumors.

The clearance follows the agency's Priority Review designation in July 2026 and an earlier Breakthrough Therapy Designation in February 2026.

Pivotal OrigAMI-4 Trial Results

Regulators based the decision on Cohort 1 of the Phase 1b/2 OrigAMI-4 trial, which investigators presented at the 2026 American Society of Clinical Oncology Annual Meeting and published in the Journal of Clinical Oncology.

Among 102 evaluable participants, the therapy produced a confirmed 42% overall response rate. Complete responses occurred in 15% of patients—representing one-third of responders—while 28% achieved partial responses.

Additionally, 56% of responders maintained their response for more than six months. Continued approval remains contingent upon clinical verification in the ongoing Phase 3 OrigAMI-5 trial.

JNJ Price Action: Johnson & Johnson shares were up 0.25% at $272.99 at the time of publication on Friday. The stock is approaching its 52-week high of $282.01, according to Benzinga Pro data./p> div class="bz-read-next-block" data-variant="card" data-news-mode="manual" >

strong> Read Also: a href="https://www.benzinga.com/crypto/cryptocurrency/26/11/62972786/trump-linked-world-liberty-plans-buyback-as-wlfi-falls-8" target="_blank" rel="noopener"> Trump-Linked World Liberty Plans Buyback as WLFI Falls 8%/a> /strong> /p>

Image via Shutterstock